George Medicines Completes Recruitment of First Phase III Hypertension Trial Investigating Novel Single-Pill Triple Combination Candidate GMRx2

access to effective treatment. The development of GMRx2 as a single-pill triple combination therapy has the potential to revolutionize hypertension treatment by providing a convenient and effective option for patients. &nbsp The completion of patient recruitment for the Phase III trial is a significant milestone for George Medicines. This achievement demonstrates their commitment to advancing me..